ストックスクリーナーアプリを入手
2.51
0.00%
0.00
アフターアワーズ：
2.51
前日終値:
$2.51
開ける：
$2.51
24時間の取引高:
919.05K
Relative Volume:
0.70
時価総額：
$230.62M
収益：
-
当期純損益:
$-36.12M
株価収益率:
-6.5297
EPS:
-0.3844
ネットキャッシュフロー:
$-28.42M
1週間 パフォーマンス:
-4.92%
1か月 パフォーマンス:
-25.30%
6か月 パフォーマンス:
+87.31%
1年 パフォーマンス:
+197.75%
1日の値動き範囲:
$2.43
$2.60
1週間の範囲:
$2.321
$2.83
52週間の値動き範囲:
$0.49
$3.62
Context Therapeutics Inc Stock (CNTX) Company Profile
名前
Context Therapeutics Inc
セクター
電話
267-225-7416
住所
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
2.51 | 230.62M | 0 | -36.12M | -28.42M | -0.3844 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.85 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-18 | 開始されました | Guggenheim | Buy |
| 2025-04-21 | 開始されました | William Blair | Outperform |
| 2025-01-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-11-25 | 開始されました | D. Boral Capital | Buy |
| 2024-05-16 | 開始されました | Piper Sandler | Overweight |
Context Therapeutics Inc (CNTX) 最新ニュース
Targets Report: Can Context Therapeutics Inc maintain sales growth2026 PreEarnings & Entry and Exit Point Strategies - baoquankhu1.vn
Rally Mode: What makes Context Therapeutics Inc stock attractive todayWeekly Trend Recap & Stock Market Timing Techniques - baoquankhu1.vn
Is Context Therapeutics Inc likely to announce a buybackMarket Activity Report & Safe Entry Zone Identification - baoquankhu1.vn
History Review: What is Context Therapeutics Incs 5 year growth outlookTrade Analysis Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
CNTX Earnings History & Surprises | EPS & Revenue Results | CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) - ChartMill
Investment Report: Will Context Therapeutics Inc stock go up in YEAR2026 Opening Moves & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Neogen names Jennifer Evans Stacey as chief legal officer - Investing.com
Food safety company Neogen taps biotech lawyer for legal, compliance post - Stock Titan
William Blair Initiates Coverage of Context Therapeutics (CNTX) with Outperform Recommendation - MSN
Breakouts Watch: How does Context Therapeutics Inc compare to its peers2026 Earnings Surprises & Growth Focused Entry Point Reports - baoquankhu1.vn
JonesTrading Remains a Buy on Context Therapeutics (CNTX) - The Globe and Mail
Buyout Rumor: Is Context Therapeutics Inc stock risky to hold now2026 Gainers & Long-Term Capital Growth Strategies - baoquankhu1.vn
JonesTrading Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Context Therapeutics Gains FDA Fast Track for CTIM-76 - The Globe and Mail
Published on: 2026-04-03 00:59:30 - baoquankhu1.vn
Context Therapeutics Shares Gain on FDA Fast Track Designation for Ovarian Cancer Drug - marketscreener.com
Context Therapeutics wins FDA fast-track status (CNTX:NASDAQ) - Seeking Alpha
Context Therapeutics' CTIM-76 Wins FDA Fast Track; Phase 1a Interim Data Due June 2026 - TradingView — Track All Markets
FDA grants Fast Track to Context Therapeutics (CNTX) CTIM-76 in platinum-resistant ovarian cancer - Stock Titan
Context Therapeutics Receives FDA Fast Track Designation for CTIM-76 in Platinum-Resistant Ovarian Cancer - Quiver Quantitative
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy - The Manila Times
Context Therapeutics Announces CTIM-76 Receives FDA Fast - GlobeNewswire
FDA fast-tracks Context drug for hard-to-treat ovarian cancer - Stock Titan
S P Trends: Can Context Therapeutics Inc maintain sales growth2026 Sector Moves & AI Based Trade Execution Alerts - baoquankhu1.vn
Support Test: Will Context Therapeutics Inc stock go up in YEARLayoff News & Fast Entry Momentum Alerts - baoquankhu1.vn
Context Therapeutics (NASDAQ:CNTX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - marketbeat.com
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Q1 EPS Forecast for Context Therapeutics Lowered by Analyst - MarketBeat
Gains Recap: What makes Context Therapeutics Inc stock attractive todayPortfolio Value Report & Technical Buy Zone Confirmations - baoquankhu1.vn
Insider Sell: Is Context Therapeutics Inc stock risky to hold now2026 Historical Comparison & Real-Time Volume Trigger Notifications - baoquankhu1.vn
HC Wainwright Brokers Reduce Earnings Estimates for CNTX - MarketBeat
Context Therapeutics (NASDAQ:CNTX) and Clearmind Medicine (NASDAQ:CMND) Head-To-Head Contrast - Defense World
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Context Therapeutics (NASDAQ:CNTX) Given Buy Rating at D. Boral Capital - Defense World
Context Therapeutics' (CNTX) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from Guggenheim - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Price Target Raised to $7.00 - MarketBeat
Context Therapeutics 2025 Annual Report: Business Strategy, Risk Factors, Clinical Pipeline, and Regulatory Insights - Minichart
Context Therapeutics Reports Full Year 2025 Operating and Financial Results - National Today
According to the latest financial data, biopharmaceutical company Context Therapeutics Inc. (Context Therapeutics) held total cash and cash equivalents of $66 million as of December 31, 2025. - Bitget
Context Therapeutics Highlights Evolving T Cell Engager Pipeline - TipRanks
Context Therapeutics (NASDAQ:CNTX) Issues Quarterly Earnings Results - MarketBeat
Context Therapeutics Reports Full Year 2025 Operating And Financial Results - TradingView
Context Therapeutics Inc. Reports Financial Results and Upcoming Milestones for CTIM-76 and CT-95 Trials - Quiver Quantitative
Context updates corporate presentation, flags interim CTIM-76/CT-95/CT-202 milestones; cash runway into mid-2027 - tradingview.com
Context Therapeutics (NASDAQ: CNTX) outlines T‑cell engager trials and cash runway - Stock Titan
Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) EstimateContext Therapeutics (NASDAQ:CNTX) - Benzinga
With $66M left, Context targets 2 cancer trial updates in 2026 - Stock Titan
CNTX: Net loss rose to $36.1M in 2025; $66M cash funds operations into mid-2027, more capital needed - tradingview.com
Context Therapeutics (NASDAQ: CNTX) advances three T cell engager programs - Stock Titan
Context Therapeutics Inc (CNTX) 財務データ
収益
当期純利益
現金流量
EPS
Context Therapeutics Inc (CNTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):